Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 5, 2010

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Partial Onset Seizures
Interventions
DRUG

Oxcarbazepine

Trial Locations (24)

460-0004

NPC Investigative Site, Nagoya

474-8710

NPC Investigative Site, Ōbu

790-8524

NPC Investigative Site, Matsuyama

814-0180

NPC Investigative Site, Fukuoka

041-1111

NPC Investigative Site, Kameda-gun

060-8648

NPC Investigative Site, Sapporo

670-8540

NPC Investigative Site, Himeji

658-0032

NPC Investigative Site, Kobe

244-0842

NPC Investigative Site, Yokohama

861-1196

NPC Investigative Site, Kōshi

945-8585

NPC Investigative Site, Kashiwazaki

879-5593

NPC Investigative Site, Yufu

710-8522

NPC Investigative Site, Kurashiki

700-8558

NPC Investigative Site, Okayama

572-0085

NPC Investigative Site, Neyagawa

330-8777

NPC Investigative Site, Saitama

524-0022

NPC Investigative Site, Moriyama-shi

420-8688

NPC Investigative Site, Shizuoka

329-0498

NPC Investigative Site, Shimotsuke

113-8431

NPC Investigative Site, Bunkyo-ku

502-8558

NPC Investigative Site, Gifu

950-2085

NPC Investigative Site, Niigata

355-0008

NPC Investigative Site, Saitama

990-0876

NPC Investigative Site, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Nobelpharma

INDUSTRY